Vantictumab, formerly identified as OMP18R5, represents a novel cloned agent designed with specifically inhibit bone associated protein 18R5. The approach is currently developed by the company in possible uses in https://bookmark-template.com/story28398681/vantictumab-the-thorough-dive-into-omp18r5-engineered-immune-agent